Detalles de la búsqueda
1.
Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.
Mult Scler;
30(3): 336-344, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38247138
2.
Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina.
Neurol Sci;
45(2): 379-389, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38159147
3.
Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting.
Mult Scler;
29(10): 1240-1249, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37491849
4.
Disability outcomes in NMOSD and MOGAD patients: data from a nationwide registry in Argentina.
Neurol Sci;
44(1): 281-286, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36166174
5.
Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM).
Neurol Sci;
41(11): 3329-3335, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32840711
6.
Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM).
Neurol Sci;
41(6): 1513-1519, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-31960250
7.
Correction to: Clinical and demographic characteristics of primary progressive multiple sclerosis in Argentina: Argentinean registry cohort study (RelevarEM).
Neurol Sci;
42(12): 5441, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34557969
8.
School performance as a marker of cognitive decline prior to diagnosis of multiple sclerosis.
Mult Scler;
21(7): 945-52, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25344372
9.
Real-World Effectiveness and Safety of Cladribine in Multiple Sclerosis: Longitudinal Data From the Nationwide Registry in Argentina.
Clin Neuropharmacol;
2024 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38776535
10.
Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings.
J Neurol;
2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38630312
11.
Barriers to access and unmet needs to neuromyelitis optica spectrum disorders care in an Argentinean cohort.
Mult Scler Relat Disord;
70: 104485, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36610362
12.
Serological response to SARS-CoV-2 vaccines in patients with multiple sclerosis in Argentina.
Medicina (B Aires);
83(3): 358-365, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37379532
13.
Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies.
Mult Scler J Exp Transl Clin;
9(1): 20552173231154712, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36846108
14.
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina.
Mult Scler Relat Disord;
79: 104935, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37634468
15.
Mortality of neuromyelitis optica spectrum disorder patients in an Argentinean population: A study from the RelevarEM registry.
Mult Scler J Exp Transl Clin;
9(4): 20552173231205444, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37854639
16.
Evaluation of the times of disability progression and related factors in patients with primary progressive multiple sclerosis from Argentina.
Mult Scler Relat Disord;
58: 103483, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35032883
17.
Rebound activity after fingolimod cessation: A case - control study.
Mult Scler Relat Disord;
57: 103329, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35158443
18.
Accumulative risk of clinical event in high-risk radiologically isolated syndrome in Argentina: data from the nationwide registry RelevarEM.
J Neurol;
269(4): 2073-2079, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34491406
19.
Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina.
Mult Scler Relat Disord;
58: 103466, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34929456
20.
Clinical and demographic characteristics of male MS patients included in the national registry-RelevarEM. Does sex or phenotype make the difference in the association with poor prognosis?
Mult Scler Relat Disord;
58: 103401, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35216784